Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on July 15, 2024, with the earliest event reported dated August 1, 2024. The filing discloses significant changes to the Company's executive leadership, specifically the appointment of a new Chief Financial Officer and the departure of the former Principal Accounting Officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Appointment of CFO: The Board appointed Robert M. Infarinato as Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective August 1, 2024.
- Departure of Principal Accounting Officer: Caitlin Kontulis ceased serving as Principal Accounting Officer effective August 1, 2024. Her employment terminates on August 31, 2024, after which she is expected to serve in a part-time advisory capacity.
Compensation and Management Commentary
Mr. Infarinato's appointment is governed by an Offer Letter dated July 16, 2024. Key terms include:
- Base Salary: $180,000 annually.
- Annual Bonus: Eligible for up to 30% of the base salary based on performance goals.
- Employment Status: At-will employee with no specified term.
- Benefits: Eligible for the 2020 Long Term Incentive Plan and standard executive benefits.
- Indemnification: The Company will enter into an indemnification agreement with terms similar to those filed in the Company's 2024 Form 10-K.
Mr. Infarinato brings over 40 years of experience in the pharmaceutical and biotech industries, including prior roles at Cutanea Life Sciences, Inc., and Abington Health Systems.
Investor Verification Checklist
- Verify the transition timeline between Ms. Kontulis's departure and Mr. Infarinato's start date to ensure no gap in financial reporting oversight.
- Review the full text of the Offer Letter (Exhibit 10.1) for specific performance metrics tied to the bonus structure.
- Confirm the terms of the part-time advisory role for Ms. Kontulis to assess potential ongoing conflicts or costs.
- Check subsequent filings for any updates on the Company's financial position following this leadership change.